Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Immediate release morphine · 1 trial · 2 indications
To determine the time to onset of meaningful breathlessness relief of fentanyl buccal tablet (FBT) in comparison to immediate-release morphine (IRM)
| Arm | Type | Description |
|---|---|---|
| Fentanyl | EXPERIMENTAL | Fentanyl buccal tablet Dosage: 100µg - 600 µg Fentanyl (to be determined by titration) Administration: buccal administration (tablet) |
| Immediate release morphine | ACTIVE_COMPARATOR | Immediate release morphine, solution Dosage: Start with a minimum of 5mg (to be determined by titration) |
| Name | Type | Description |
|---|---|---|
| Fentanyl | DRUG | - |
| Immediate release morphine | DRUG | - |
Inclusion criteria: 1. Histologically or cytologically proven cancer of any entity which is non-curable as judged by the referring physician or investigator 2. To be an inpatient during the study 3. Refractory breathlessness - this study applies only to 'refractory breathlessness ' and is defined: ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
Immediate release morphine is an investigational small molecule being studied for the relief of episodic breathlessness, also known as paroxysmal dyspnea, in cancer patients. It is currently in Phase 2 clinical development for this oncology-related condition.
Immediate release morphine is being developed by Teva Pharmaceutical Industries Limited, a company traded on the stock exchange under the ticker TEVA. The drug is currently in Phase 2 clinical trials for cancer-related episodic breathlessness.
Immediate release morphine is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy for treating episodic breathlessness in cancer patients.
Immediate release morphine has one completed clinical trial, identified as NCT04635852. This Phase 2 study, titled 'Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Cancer Patients,' enrolled 10 participants in Germany and was an active-controlled, randomized trial.
No, immediate release morphine is not the same as fentanyl buccal tablet. The clinical trial NCT04635852, which studied immediate release morphine, compared it against a fentanyl buccal tablet as an active control. These are two distinct drug products.